BREGAL-MILESTONE
13.5.2024 06:01:37 CEST | Business Wire | Press release
Bregal Milestone, a leading European technology and software private equity firm and majority owner of Allshares, a pioneering compensation and long-term incentive software and services provider, today announced the acquisition of Novare Pay and the appointment of Michael Ingelög as Chair of the Allshares Board.
Novare Pay, based in Stockholm, is acclaimed for its reputation as a high-growth, high-margin European compensation services provider with a strong Nordic heritage. With an impressive clientele including leading multinational enterprises, Novare Pay's integration into the Allshares ecosystem will translate to an enhanced end-to-end digital turnkey offering to its over 630 clients spanning more than 40 countries worldwide. The acquisition of Novare Pay further fortifies Allshares' leadership position as one of Europe’s leading compensation software and services providers, with augmented and strengthened capabilities across compensation data and analytics, incentives, and governance. At closing, Novare Pay will rebrand and operate under the Allshares name.
Commenting on the landmark acquisition, Erika Andersson, CEO of Novare Pay, expressed her enthusiasm, stating, "Over the years, we have built a strong and diversified customer footprint and a talented team operating from our strategic hubs in Stockholm, Oslo, and London. Partnering with Allshares presents an exciting opportunity to not only enhance our service delivery with tech-forward compensation software but also to help spearhead a transformative shift in the European compensation landscape."
Cyrus Shey, Co-Founder and Managing Partner at Bregal Milestone, echoed Andersson's sentiments, saying, "We extend a warm welcome to Erika, Andreas, and the entire Novare Pay team as they join the Allshares family. Leveraging Novare Pay's specialized expertise in pay, remuneration, and compensation, alongside its client-centric approach, this partnership will help propel Allshares to new heights across Europe, re-affirming their steadfast commitment to delivering leading compensation solutions that drive high performance for both private and publicly listed customers. With Michael's appointment as Chair, we are confident in our ability to harness this momentum and further strengthen Allshares’ position as an industry leader."
As Chairman Michael Ingelög brings his wealth of experience as a seasoned CEO and board executive with deep knowledge of the Nordic and European markets. In response to his appointment and the acquisition of Novare Pay to the Allshares family, Ingelög commented, “Allshares’ distinctive solutions built and delivered by industry experts underpinned my decision to join as Chair of the Board. With the recent addition of Novare Pay to the Allshares family, Allshares is poised to enhance its offerings even further and truly transform the European compensation landscape. I'm thrilled to help shape the company’s future, alongside management and the board.”
The terms of the transaction were not disclosed and are subject to customary closing conditions.
About Bregal Milestone
Bregal Milestone is a leading European software and technology private equity firm with c.€1.3 billion of capital raised since inception. The firm provides growth capital and operational support to build market-leading technology companies. Bregal Milestone is part of Bregal Investments, a leading global investment platform with assets under management of over €18 billion. Bregal Milestone was recognised by GrowthCap as one of the Top Growth Equity Firms of 2023. For more information, visit www.bregalmilestone.com or follow us on LinkedIn.
About Allshares
Allshares is a market leader for equity plan design and administration in the Nordics. Trusted by leading multinational enterprises, Allshares serves approximately 300 multinational public and private enterprise customers in more than 100 countries with an end-to-end digital turnkey solution for equity plan management. Companies and participants can use its proprietary software and services to administer share plans in full compliance with relevant regulations, legal, and tax frameworks, as well as deliver seamless and automated IFRS reporting of share plans to companies. For more information, visit www.allshares.com
About Novare Pay
Novare Pay is a premier provider of remuneration services to multinationals. With a dedicated team of over 50 seasoned specialists stationed across Stockholm, Oslo, and London, Novare Pay offers bespoke compensation services and analytics tailored to clients' needs. Novare Pay boasts an impressive track record of high-growth, high-margin fundamentals, while serving over 900 clients in more than 60 countries. For more information, visit www.allshares.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240512957761/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom